Providing novel possibilities for all life.

↑ここにファーストビュー用のマスクあります↑

PLATFORM


Our revolutionary technology, DIO (Directly Induced Oocyte), is capable of producing an extremely large yield of fertilizable egg cells at a minimal cost in a fraction of the time.
We aim to create state-of-the-art solutions to a myriad of problems surrounding pregnancy, including infertility as a result of age and hereditary disorders.

Our revolutionary technology, DIO (Directly Induced Oocyte), is capable of producing an extremely large yield of fertilizable egg cells at a minimal cost in a fraction of the time.
We aim to create state-of-the-art solutions to a myriad of problems surrounding pregnancy, including infertility as a result of age and hereditary disorders.

↑ここにリードエリア用の白いマスクあります↑

Grow with Us

We’re looking for high-performing individuals who are passionate about science and excited to work in a collaborative environment fueled by a rigorous or entrepreneurial culture.

We’re looking for high-performing individuals who are passionate about science and excited to work in a collaborative environment fueled by a rigorous or entrepreneurial culture.

MEMBER

President and CEO

Kazuma Kishida

Born in 1995.
After graduating from Waseda University in 2020, engaged in investment banking business at the US investment bank Houlihan Lokey.
In 2021, he co-founded Dioseve Inc. and became CEO of the company.

Scientific Advisor

Nobuhiko Hamazaki Ph.D.

Born in 1987.
Worked as a researcher and associate professor at the Kyushu University School of Medicine from 2015 to 2020. Currently serving as a HHMI special researcher at the University of Washington in the USA.
In 2021 he co-founded Dioseve Inc. and became the chief Scientific officer of the company.

Senior Scientist

Kaharul Kahar

Born in 1990.
Graduated from Universiti Kuala Lumpur Royal College of Medicine Perak in 2014 and engaged in research at Kyushu University’s Hayashi Laboratory.
Joined Dioseve as Senior Scientist in 2021.

Senior Scientist

Keitaro Yamane Ph.D.

Born in 1981.
Obtained Doctorate degree from faculty of medicine, Osaka University in 2012 and worked at Edinburg University as a post doctral fellow. In 2020 engaged in Japanese pharmatheutical company.
Joined Dioseve as Senior Scientist in 2022

Cell Culture Specialist

Orie Hikabe Ph.D.

Born in 1987.
Graduated from Keio University School of Medicine and obtained Doctorate degree from Kyushu University’s Hayashi Laboratory.
Joined Dioseve in 2022.

Scientist

Scott C. Eisenhower

Born in 1992.
Graduated from Arizona State University and joined P&G in 2015.
Moved to Japan to pursue a graduate education at the University of Tsukuba in 2017.
Joined Dioseve in 2022.

Scientist

Etsuko Okada

Born in 1976.
Engaged in Sanwa Kagaku Kenkyusho as a Technician 2013.
Academic Researcher at Kumamoto University in 2019.
Joined Dioseve in 2022.

External Advisor

Yoshinori Shiiki

Graduated from the Department of Biopharmaceuticals, Kyoto Pharmaceutical University.
Launched the Clinical Development Department at Eli Lilly Japan and Parexel International, and since 2015, General Manager of of JConsulting Management Department.

External Advisor

Nobuhiko Suganuma
M.D., Ph.D.

Professor emeritus of Kyoto Univ. since 2018. Graduated from the Graduate school of Medicine, School of Medicine, Nagoya University. Director of Japan Society of Fertilization and Implantation. Director of Japan Society of assisted Reproduction.
Board Chairman of Japan Society for
Uterus Transplantation.

INVESTORS

FEATURED IN

↑ここにアクセストップのマスクあります↑

ACCESS

Headquarters

2-3-11 Nihonbashihoncho, Chuo-ku, Tokyo,
103-0023

Tokyo Laboratory

5-25-18 Hongo, Bunkyo-ku, Tokyo, 133-0033

Kumamoto Laboratory

2-2-1, Honjo, Chuo-ku, Kumamoto-shi, Kumamoto Kumamoto University, 860-8556